Investment in COVID-19 testing & diagnostics

Together with The Global Fund, FIND is co-convener of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Partnership. The ACT Accelerator is a global collaboration to accelerate the development, production and equitable access to new COVID-19 diagnostics, therapeutics and vaccines.


In May 2020, the Coronavirus Global Response pledging event called on the global community and political leaders to support this landmark collaboration, and for donors to provide the necessary resources so that testing inequalities do not jeopardize our global pandemic response. The Global Citizen and the European Commission also announced a new campaign, Global Goal: Unite for Our Future, whose aim is to ensure that everyone, everywhere in the world, has access to COVID-19 tests, treatments, and vaccines and to lessen the impact of COVID-19 on the world’s most vulnerable people.












Investment for diagnostics & testing committed by:

COVID-19 diagnostics & testing investment case

We have an opportunity to contain the humanitarian and economic fallout of the COVID-19 pandemic. Without mass testing – which relies on availability of high-performing, rapid tests – the disease will continue to spread. Innovation and scale up of these tests must be accelerated for deployment in all countries. For low- and middle-income countries, this investment would contribute to saving 9 million lives, and strengthen health systems to overcome the COVID-19 pandemic.

An investment of US$6 billion is required to harness innovation and secure access to vital diagnostic tests over the next 12 months for low- and middle-income countries.

US$2 billion of this is required immediately to expedite development, manufacturing and scale-up of the rapid tests that will enable mass testing to be introduced globally – as well as procurement of tests to fill critical short-term gaps in low-income countries.



More information

For more information, or to discuss how you can support diagnostics and testing for COVID-19, please contact us.

Quick links